























































Acta Derm Venereol 2017; 97: 685–691
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta




Staphylococcal enterotoxins have been shown to pro-
mote lymphoma-associated immune dysregulation. 
This study examined changes in the skin microbiome 
of parapsoriasis compared with intact skin. Swab mi-
crobiome specimens were taken of the parapsoriasis 
lesions of 13 patients. Control samples were taken 
from contralateral healthy sides of the body. Micro-
biotas were characterized by sequencing the V1–V3 
region of the 16S ribosomal RNA bacterial genes on 
the Illumina MiSeq platform. The most common ge-
nera in the microbiome data were Propionibacterium 
(27.13%), Corynebacterium (21.20%) and Staphylo-
coccus (4.63%). Out of the Staphylococcus sequences, 
39.6% represented S. epidermidis, with the rest inclu-
ding S. hominis, S. capitis and unidentified species. 
No significant differences were observed between the 
patients’ parapsoriasis and contralateral healthy skin 
or between large- and small-plaque parapsoriasis. No-
table interpersonal variation was demonstrated. The-
se results suggest that parapsoriasis is not associated 
with significant alterations in the cutaneous bacterial 
microbiome.
Key words: skin microbiome; cutaneous microbial diversity; 
cutaneous microbes; large-plaque parapsoriasis; small-plaque 
parapsoriasis; cutaneous T-cell lymphoma.
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Novel molecular techniques have greatly improved our knowledge of the skin microbiome (1). Genomic 
studies with targeted sequencing of parts of the gene co-
ding for ribosomal 16S RNA have shown that cutaneous 
microbial colonization is more complex than previously 
thought (2). Studies characterizing the microbiota of 
different body sites in humans have revealed that the 
spectrum of micro-organisms varies depending on nu-
merous intrinsic and extrinsic factors (3–5). Common 
skin diseases, such as atopic dermatitis, have been linked 
to specific changes in the microbiome (6, 7). However, 
it remains unclear whether these changes are caused by 
microbes, or are secondary to factors such as changes in 
the skin barrier or immunological factors (8).
Parapsoriasis refers to a group of cutaneous lympho-
proliferative disorders, ranging from a chronic dermati-
tis-like picture at one end to a picture mimicking patch-
stage cutaneous T-cell lymphoma (CTCL) at the other 
(9). Clinical findings are traditionally used to classify the 
disease into small-plaque parapsoriasis (SPP), i.e. clas-
sical digitate dermatitis, and large-plaque parapsoriasis 
(LPP). Both subtypes may remain indolent for many 
years, but LPP progresses to CTCL, primarily mycosis 
fungoides, in up to 30% of cases (10), and parapsoriasis 
is difficult to differentiate from early CTCL by clinical 
features, histopathological characteristics or immuno-
phenotype (11). There is no marker to identify cases 
prone to progression.
Various studies have confirmed the intimate interaction 
between skin microbiota and the host’s immune system 
(11, 12). It has become apparent that, in addition to its 
physical characteristics, the skin’s innate immune system, 
together with the resident commensal microbes, protects 
the skin by providing a functional immunological barrier. 
It was recently shown that Staphylococcal enterotoxin 
A (SEA) from the affected skin of patients with CTCL 
induces in vitro interleukin (IL)-17 production in primary 
malignant T cells of patients with Sézary syndrome when 
co-cultured with autologous non-malignant T cells (but 
not in monocultures of malignant T cells) (13). Since 
parapsoriasis often precedes mycosis fungoides (10), 
which is the most common form of CTCL, the aims 
of this study were to investigate whether parapsoriasis 
lesions would have a different skin surface microbiome 
compared with the individual’s healthy (non-lesional) 
skin sites, and to explore the association of any specific 
bacteria with the chronic T-cell proliferation underlying 
parapsoriasis. A further aim was to investigate whether 
the skin microbiome (swab sampling) could offer a 
cost-effective and non-invasive diagnostic method to 
study parapsoriasis in patients whose skin is otherwise 
repeatedly biopsied. 
METHODS
Patients and skin sampling
The clinical part of the study was carried out in January–May and 
September of 2014 at the Department of Dermatology and Aller-
gology, Helsinki University Hospital, Helsinki, Finland. A total 
of 13 study subjects (6 with SPP and 7 with LPP) were recruited 
from patients with histopathologically confirmed parapsoriasis 
and followed up at the university clinic. All patients gave their 
informed consent. The skin characteristics and medical history of 
all the study subjects are presented in Table I. None of the subjects 
had received antibiotics or ultraviolet (UV) phototherapy within 
the previous 12 months, and none were predisposed to bacterial 
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or fungal skin infections. All patients were examined by the same 
experienced dermatologist. The clinical picture was documented 
using close-up photographs prior to the incisional biopsy. The 
ethics committee of the University of Helsinki approved the study 
protocol (approval number 12/13/03/01/2012). 
Skin microbiome samples were collected under sterile conditions 
with a sterile swab (Copan Flocked Swab®, Copan Diagnostics 
Inc., Murrieta, CA, USA). The swab was first dipped in a buffer 
solution (sterile 0.15 mol/l NaCl with 0.1% Tween 20), then rubbed 
approximately 20 times in both directions over the target skin area. 
Lesional specimens were obtained directly from the parapsoriasis 
patches. The borders of the individual parapsoriasis lesion were not 
traversed and the skin was not manipulated or disinfected before 
sampling. Control samples were collected in a similar manner 
from healthy skin on the contralateral side of the same patient’s 
body. No control group of healthy individuals was analysed. The 
approach of using the patient’s own healthy skin as control was 
chosen to avoid inter-individual variation in the microbiome (4, 14) 
and because the patients were already diagnosed with parapsoria-
sis, we wanted to investigate whether skin swab specimens could 
provide additional information to traditional biopsies. In order to 
reduce the risk of sample cross-contamination, a new pair of sterile 
gloves was used for each separate sampling procedure. Both the 
lesion and the healthy skin were sampled twice. Samples were 
deposited immediately in sterile 1.5-ml Eppendorf® tubes (Ep-
pendorf AG, Hamburg, Germany), frozen with liquid nitrogen, 
and stored at –80ºC. 
DNA extraction, PCR and sequencing
Sample DNA was extracted with the FastDNA Spin Kit for Soil 
(MP Biomedicals, LLC, Santa Ana, CA, USA) according to the 
manufacturer’s instructions. Each extraction batch included a kit 
blank with no template DNA. The PCR protocol consisted of 2 
steps. The first step was run with 2 × 25-µl technical replicates of 
each sample, with the amount of template DNA ranging from 23 to 
58 ng. The primers for the first step consisted of universal bacterial 
primers targeting the V1–V3 regions of the 16S rRNA gene, pA 
(AGAGTTTGATCMTGGCTCAG) (15) and pD’ (GTATTACCG-
CGGCTGCTG) (16) and partial Illumina TruSeq adapter (Illumina 
Inc., San Diego, CA, USA) sequences (ATCTACACTCTTTCC-
CTACACGACGCTCTTCCGATCT and GTGACTGGAGTT-
CAGACGTGTGCTCTTCCGATCT, respectively) added to the 
5’ ends of the primers. The PCR program was as follows: initial 
DNA denaturation at 98°C, followed by 15 cycles at 98°C for 10 
s, 65°C for 30 s, and 72°C for 10 s, and final extension for 5 min 
at 72°C. Each PCR run included a PCR blank with no template 
DNA. Before the second step, the PCR products were purified with 
Exonuclease I (Thermo Scientific) and Thermosensitive Alkaline 
Phosphatase (FastAP; Thermo Scientific), Thermo Fisher Scienti-
fic, Waltham, CA, USA. Five ml per sample of the first PCR step’s 
products were used for the second PCR step, which was run with 
full-length TruSeq P5 and Index-containing P7 adapters, and a 
PCR program identical to the first, except with 18 cycles. The final 
PCR products were purified with Agencourt AMPure XP magnetic 













(years prior to sampling) Concomitant diseases
LPP 1 F/37 2012 (2) Flank None Asthma, allergic rhinitis
LPP 3 M/86 2011 (3) Upper arm None Hypothyroidism, hypertension, 
hypercholesterolaemia
LPP 4 M/81 2009 (5) Upper arm NB-UVB 2011 (3) Coronary artery disease, hypertension, 
hypercholesterolaemia, prostatic 
hyperplasia, arthrosis
LPP 6 F/69 2010 (4) Upper arm None Recurrent deep vein thrombosis, 
nephrolithiasis, colonic diverticulitis
LPP 10 M/60 2008 (6) Flank None Hypertension, gout, prostatic 
hyperplasia
LPP 11 M/57 2001 (13) Upper arm NB-UVB 2013 (1), bath PUVA 2012 (2), bath PUVA 2011 (3) None
LPP 12 F/59 2002 (12) Thigh Bath PUVA 2010 (4), NB-UVB 2009 (5), NB-UVB 2008 (6), 
NB-UVB 2006 (8), oral PUVA 2003 (11)
None
SPP 2 M/73 2002 (12) Flank 2012 NB-UVB (2), 2011 NB-UVB (3), 2005 SUP (9), 2003 
SUP (11), 2001 SUP (12)
Type 2 diabetes, hypertension, 
hypercholesterolaemia
SPP 5 M/47 2003 (11) Flank 2013 NB-UVB (1), NB-UVB 2008 (6), SUP 2008 (6), SUP 
2004 (10)
None
SPP 7 F/66 2008 (6) Abdomen NB-UVB 2013 (1) Hypertension, hypercholesterolaemia
SPP 8 M/63 2012 (2) Abdomen None Hypertension, migraine, arthrosis
SPP 9 M/71 2010 (4) Thigh NB-UVB 2011 (3), NB-UVB 2010 (4) Hypertension, hypercholesterolaemia, 
prostatic hyperplasia, arthrosis
SPP 13 F/52 2013 (1) Upper arm None None
LPP: large-plaque parapsoriasis; SPP: small-plaque parapsoriasis; NB-UVB: narrow-band ultraviolet B phototherapy; SUP: selective ultraviolet phototherapy; PUVA: 
psoralen ultraviolet A photochemotherapy.
Table II. Overall abundances of the 10 most common genera in the microbiome data (% out of total sequence reads)
Phylum Class Order Family Genus % of sequences
Actinobacteria Actinobacteria Actinomycetales Propionibacteriaceae Propionibacterium 27.13
Actinobacteria Actinobacteria Actinomycetales Corynebacteriaceae Corynebacterium 21.20
Firmicutes Bacilli Bacillales Staphylococcaceae Staphylococcus 4.63
Actinobacteria Actinobacteria Actinomycetales Micrococcaceae Micrococcus 3.58
Proteobacteria Betaproteobacteria Burkholderiales Burkholderiaceae Ralstonia 3.30
Actinobacteria Actinobacteria Actinomycetales Dietziaceae Dietzia 3.02
Firmicutes Clostridia Clostridiales Clostridiales Incertae Sedis XI Anaerococcus 2.72
Proteobacteria Betaproteobacteria Burkholderiales Burkholderiaceae Burkholderia 2.21
Proteobacteria Betaproteobacteria Burkholderiales Comamonadaceae Curvibacter 2.05
Firmicutes Bacilli Lactobacillales Streptococcaceae Streptococcus 1.87
Unclassified Unclassified Unclassified Unclassified Unclassified 10.19
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beads (Beckman Coulter Finland Oy, Vantaa, Finland) and pooled. 
All samples were sequenced in a single run on a MiSeq Sequencer 
(Illumina) using v2 600 cycle kit paired-end (325 bp + 285 bp). 
Raw data from sequencing have been uploaded to the European 
Nucleotide Archive (accession no PRJEB15287).
Sequence data analysis and statistics
Cutadapt (17) was used to trim primers and low-quality ends of 
sequences from the data, with the parameters -q 30 for both reads 
and -m 200 for the forward, -m 180 for the reverse read. Pairing 
the reads, further sequence quality control and taxonomic classi-
fication were done with mothur (18) following the recommended 
procedure for MiSeq-sequenced 16S rRNA data (19). All singleton 
Operational Taxonomic Units (OTUs) were trimmed before further 
analysis. Because of recent studies about a possible link between 
Staphylococcus enterotoxins and cutaneous lymphoma-associated 
immunological dysregulation, we further explored the sequences 
classified as Staphylococcus using oligotyping (20).
Visualization and statistics were performed in R (21). The 
final taxonomy and OTU tables from mothur were exported to 
the phyloseq (22) R package. Based on their high abundance in 
blanks, all bacteria of the genera Halomonas and Shewanella 
were discarded as likely contaminants. Since there were duplicate 
samples (each patient location was sampled twice), these were 
merged before further analyses. For beta diversity comparisons 
with Bray-Curtis dissimilarity, the data was subsampled with 
phyloseq (23) to the lowest amount of reads per sample, which 
was 30 285. Bray-Curtis dissimilarities were calculated and 
compared with vegan (24) (commands vegdist and adonis). Phy-
loseq was used for non-metric multidimensional scaling (NMDS) 
ordination based on the Bray-Curtis dissimilarities, as well as 
calculating the Shannon and inverse Simpson alpha diversity 
indices (commands plot_ordination and estimate_richness). 
Statistical significances of alpha diversity and pairwise beta 
diversity were assessed using the Kruskal–Wallis rank sum test 
and the Wilcoxon rank sum test with Holm-Bonferroni mul-
tiple comparison correction, with p-values ≤ 0.05 considered 
significant. Differential abundance of taxa was tested with the 
package DESeq2 (25).
RESULTS
General characteristics of the microbiome findings
The skin microbiome data for our patients with para-
psoriasis represented a total of 410 genera, 39 classes 
and 21 phyla. Eighty-nine percent of the sequences 
represented 4 phyla: Actinobacteria (class Actinobac-
teria, 59.37%), Firmicutes (predominantly the classes 
Clostridia and Bacilli, 15.02%), Proteobacteria (mostly 
Alpha-, Gamma-, and Betaproteobacteria, 12.46%) and 
Bacteroidetes (mainly Bacteroidia, 2.16%). Of these 
sequences, 10.19% remained unclassified at the phylum 
level. The most common genera in the microbiome data 
were Propionibacterium (27.13%), Corynebacterium 
(21.20%) and Staphylococcus (4.63%). The relative 
abundances of the most abundant bacterial genera are 
shown in Table II and Fig. 1.
Oligotyping was used to further characterize the po-
tential Staphylococcus species in our data. The optimal 
result, based on 2 nucleotide positions, suggested that 
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comparisons with known sequences using BLAST, the 
3 most common oligotypes represented S. epidermidis 
(39.63%), S. hominis (33.34%) and S. capitis (21.50%). 
The remaining 2 oligotypes (4.61% and 0.92%) could 
not be identified.
Microbial diversity
Alpha diversity indices (Shannon and inverse Simpson) 
were calculated for each microbiome sample, and these 
were compared statistically (Fig. 2). There was no sta-
tistically significant difference either between healthy 
(control) and lesional parapsoriasis skin (Kruskal–Wallis 
rank sum test; p > 0.34 for both indices), or between the 
small and large-plaque parapsoriasis groups (p > 0.57 
for both indices).
In all patients, the microbial communities on lesional 
parapsoriasis skin and healthy control skin were very 
similar. A non-metric multidimensional scaling (NMDS) 
ordination based on Bray-Curtis dissimilarity values, 
with samples coloured by subject, illustrates the simi-
larity of each patient’s samples (Fig. 3). The clustering 
by patient is highly statistically significant (adonis: 
p = 0.00001 and R2 = 0.88858). On the other hand, neither 
ordination nor statistical testing with adonis suggested 
any kind of a community-wide effect for sample type 
or parapsoriasis subtype (data not shown). Grouped 
comparisons of pairs of Bray-Curtis dissimilarity values 
(Fig. 4) also demonstrate that pairs of samples from the 
same subject are highly similar, whereas pairs of samp-
les from different patients, be they control vs. control, 
control vs. parapsoriasis plaque, or plaque vs. plaque, are 
equally dissimilar from one another. In other words, the 
microbiome was more alike between the same patient’s 
samples, even though one was from lesional and the 
other from healthy skin, than compared with the samples 
of other patients, regardless of sample/lesion status or 
large-/small-plaque parapsoriasis type.
Fig. 2. Box-plot of the inverse Simpson diversity of the samples, 
grouped by sample type. Lower and upper hinge of the box: 1st and 3rd 
quartiles; whiskers: 1.5 * IQR; line: median; cross: mean; grey points: 
actual values for each sample.
Fig. 3. Non-metric multidimensional scaling (NMDS) ordination 
based on Bray-Curtis dissimilarity. Colours correspond to subjects and 
shapes to sample types. The closer together 2 samples are on the plot, 
the more similar they are to each other.
Fig. 4. Box plot of Bray-Curtis dissimilarities of all possible pairs 
of samples, in which each point represents the dissimilarity of 
2 samples (the lower the value, the more similar the samples), 
grouped by type and subject of the compared samples. Lower and 
upper hinge of the box: 1st and 3rd quartiles; whiskers: 1.5 * IQR; line: 
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Comparisons of specific taxa
DESeq2 was used to search for differentially abun-
dant taxa between the sample types (healthy skin vs. 
parapsoriasis lesion). A model that was corrected for 
the subject-specific variation produced a handful of 
significant taxa, but these were particularly abundant 
in one outlier sample, and were no longer significant 
when this outlier was left out of the analysis (data not 
shown). Unfortunately, the low number of samples per 
group did not allow for reliable comparisons between 
the small and large parapsoriasis subtypes. Statistical 
comparisons of the relative abundances of the 5 Stap-
hylococcus oligotypes did not reveal any differences 
between plaques and healthy skin, or parapsoriasis 
subtypes (data not shown). 
DISCUSSION
To our knowledge, this is the first publication on the 
skin microbiome in parapsoriasis. The abundances of 
bacterial taxa (based on the 16S rRNA gene) seen in our 
study were consistent with the results of preceding skin 
microbiome studies (14, 26). Also in line with previous 
studies, we observed significant interpersonal variation 
between subjects (27) and, thus, the use of an autologous 
healthy skin site as reference was appropriate. We did not 
find any differences between the lesional parapsoriasis 
skin and healthy control skin in our patients. Considering 
that the overall skin microbiota in our subjects appear to 
be similar to those found in subjects with healthy skin 
in many previous studies (28), the results of the current 
study suggest that overgrowth of any specific bacterial 
genus is not driving parapsoriasis, nor does parapsoriasis 
alter human skin bacterial communities.
While parapsoriasis belongs to the spectrum of 
lympho proliferative diseases of the skin, the evolution of 
parapsoriasis is strongly influenced by the host’s immune 
response. Considering the previously known association 
of the skin microbiome and cutaneous immune defence 
(29, 30) it could have been expected that lesional pa-
rapsoriasis would have an effect on the microbiome, or 
vice versa, local or systemic immunological factors of 
the patients would have had an effect on the cutaneous 
microbiome (31). 
In recent studies, it has been demonstrated clearly that 
the composition of the skin microbiome is influenced 
by the host’s native and adaptive immune system due 
to a constant interaction (32). Systemically acting or 
locally effective factors of the immune system have been 
shown to impact the cutaneous microbiological diversity 
(32–34). In addition, specific environmental factors, 
such as the patient’s occupation, skin type, exposure to 
ultraviolet (UV)-light and the use of antibiotics, have 
been shown to influence the micro-organisms colonizing 
the skin (35, 36). 
Some recent studies have investigated the role of the 
microbiome in skin cancer, but this field of research has 
only just begun to explore how the skin microbiome 
might influence the development of premalignant and 
malignant skin changes (37, 38). Some parallels have 
been drawn with the gut microbiome, which has been 
shown to directly impact the risk of cancer by promoting 
inflammation (39). The skin microbiome is almost as 
diverse as the gut microbiome, and might affect the risk 
of several diseases, including cancer (40).
Multiple reasons may explain why the skin micro-
biome in the patients’ lesional parapsoriasis skin in our 
patient cohort showed no variation compared with their 
healthy control skin. One possibility would be the fact 
that the T-cell infiltration in parapsoriasis mainly occurs 
in the dermis. An epidermis of normal thickness contains 
only isolated, single atypical lymphoid cells, and there-
fore the cutaneous microbiome remains unaffected even 
in lesional skin. Another possibility would be that the 
stratum corneum is more intact in parapsoriasis than in 
other inflammatory skin diseases, e.g. atopic dermatitis, 
in which differences are seen. 
Recent studies have shown a possible link between 
Staphylococcus enterotoxins and cutaneous lymphoma-
associated immunological dysregulation (e.g. STAT3 
activation and IL-17 expression in Sézary syndrome 
peripheral blood cell co-cultures). We further explored 
the sequences classified as Staphylococcus using oli-
gotyping, but could not identify S. aureus. The role of 
Staphylococci has not been investigated in parapsoriasis 
earlier, but because of the fact that parapsoriasis belongs 
to the spectrum of cutaneous lympho proliferative dis-
orders and often precedes mycosis fungoides, the most 
prevalent type of CTCL (10), we expected to see changes 
in the skin microbiome. Specific differences between 
CTCL and parapsoriasis (T-cell infiltrate, localized and 
systemic disease), the metabolomics properties of the 
microbiome and unknown confounders may explain our 
observations. Based on these results, the role of S. aureus 
per se and SEA seem not to be relevant in parapsoriasis.
The presented observations were made in a small 
patient cohort, which should be considered as a major 
limitation of the study. In addition, we chose not to 
use a control group with healthy individuals, and such 
controls might reveal differences not seen here. The 
significant interpersonal variation and the small number 
of subjects may have masked minor differences between 
healthy and lesional skin, and elucidating them might 
only be possible in a larger cohort. In common skin 
diseases, such as atopic dermatitis, the demonstrated 
changes in the skin microbiome during disease progres-
sion and flares have been relatively characteristic, and 
this fact could be a potential target for future studies re-
lated to parapsoriasis (41, 42). Modern molecular tools 
for characterizing the skin microbiome have proved to 
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could offer new insight into parapsoriasis and cutaneous 
lymphomas (43). 
The role of the skin microbiome in parapsoriasis 
remains uncertain, but it would be important to further 
define how the microbiome changes during disease 
progression and to undertake metabolomics studies. 
Thus, as a further study we propose to compare the skin 
microbiome of large-plaque parapsoriasis with that of 
manifest cutaneous T-cell lymphoma. If changes in the 
microbiome in patients with common types of T-cell 
lymphoma can be reproduced, this would encourage 
further studies of large-plaque parapsoriasis in order 
to use disease-associated changes as a diagnostic tool. 
During disease progression of parapsoriasis a change in 
the cutaneous microbiome may be expected, as seen in 
inflammatory skin disorders such as atopic dermatitis. 
Investigation of the microbiome might therefore solve 
several aspects of the pathogenesis of parapsoriasis, 
leading to new diagnostic possibilities. 
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